In addition to CD47/SIRPα blockade, bispecific agents currently under investigation were designed to target either another cancer specific cell surface molecule concurrently expressed on the target tumor cells (i.e., CD19, CD20, PD-L1) or a cell surface molecule expressed by T cells (i.e., PD-1). The gene discussed is SIRPA; the disease is cancer.